About i2o Therapeutics
i2o Therapeutics is a Healthcare company based in Boston (United States) founded in 2019 by Samir Mitragotri and Ravi Srinivasan. Oral drug delivery solutions are provided via liquid technology platform. i2o Therapeutics has raised $53.5 million across 6 funding rounds from investors including Colorcon, Sanofi Ventures and T1D Fund. The company has 6 employees. Its focus areas include Life Sciences, Drug Delivery and Oral. Its legal entity is i2o Therapeutics, Inc. Its competitors include Lyndra, Biora Therapeutics and Cure Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
i2o Therapeutics was founded in 2019 in Boston, United States, as a biotechnology firm focused on drug delivery systems. A liquid platform is utilized by the company to enable oral administration of therapeutics. Drug molecules are protected within this technology, while permeation across the epithelial lining is enhanced for better absorption. Operations center on developing this solution for pharmaceutical applications in the oral delivery sector.
- Headquarters Boston, United States
- Employees 6
- Founders Samir Mitragotri, Ravi Srinivasan
- SectorsHealthcare
- Email••••••••
- Website i2obio.com
- Social LinkedIn
- Legal Name I2o Therapeutics, Inc
- Total Equity Funding$53.5M (USD)
in 6 rounds
- Latest Funding Round$3.5M (USD), Series A
Oct 2023
- InvestorsColorcon
& 2 more
- Employee Count6
Funding Insights of i2o Therapeutics
i2o Therapeutics has successfully raised a total of $53.5M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $3.5 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $53.5M
- Total Rounds 6
- Last Round Series A — $3.5M
- First Round $3.2M
(Mar 2020)
- Investors Count 3
All 6 funding rounds of i2o Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $3.5M | Series A | – | – | – |
| Aug 2023 | $46M | Series A | – | – | – |
| Dec 2020 | Seed | – | Colorcon | – | |
| Dec 2020 | $600,000 | Debt – Conventional | – | – | – |
| Apr 2020 | $4M | Seed | – | Sanofi Ventures, T1D Fund | – |
| Mar 2020 | $3.2M | Debt – Conventional | – | – | – |
3 investors in total: 3 institutional.
Investors in i2o Therapeutics
i2o Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Colorcon, Sanofi Ventures and T1D Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Companies developing T1D products are funded through venture philanthropy. | t1dfund.org | Boston, United States | ||
Developer of specialty excipients and corporate-backed venture capital fund focused on healthcare startups | 1961 | colorcon.com | Harleysville, United States |
Investor details for i2o Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of i2o Therapeutics
4 people are tracked at i2o Therapeutics (2 in leadership, 1 in board & advisors, 1 in team); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Samir Mitragotri | Co-Founder | Leadership |
Ravi Srinivasan | Co-Founder | Leadership |
Kurt Graves | Executive Chairman | Board & advisors |
Harrison Vener | Animal Research Technician & Wet Lab Assistant | Team |
Complete people profiles for i2o Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of i2o Therapeutics
3 dated milestones of i2o Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded i2o Therapeutics is founded.
- Funding First funding round of $3.2M.
- Funding Latest funding round, Series A, of $3.5M.
Competitors of i2o Therapeutics
i2o Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Lyndra, Biora Therapeutics and Cure Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lyndra.com | 2015 | Cambridge, United States | $305.01M | 107 | Innovates long-acting oral therapies to simplify patient medication regimens. | |
| bioratherapeutics.com | 2010 | San Diego, United States | $116.62M | 54 | Smart pills are developed for targeted gastrointestinal drug delivery. | |
| curepharmaceutical.com | 2010 | Oxnard, United States | $9.65M | 28 | Oral thin film-based drug delivery systems are developed. |
Detailed competitors of i2o Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as i2o Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about I2o Therapeutics
Complete news archive for i2o Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about i2o Therapeutics
i2o Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
i2o Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
i2o Therapeutics is a funded company, having raised a total of $53.5M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $3.2M, raised on Mar 2020.
i2o Therapeutics has 6 employees.
i2o Therapeutics was founded in 2019 in Boston, United States, as a biotechnology firm focused on drug delivery systems. A liquid platform is utilized by the company to enable oral administration of therapeutics. Drug molecules are protected within this technology, while permeation across the epithelial lining is enhanced for better absorption. Operations center on developing this solution for pharmaceutical applications in the oral delivery sector.
i2o Therapeutics's top competitors include Cure Pharmaceutical, Biora Therapeutics and Lyndra.
i2o Therapeutics has 3 investors. Key investors include Colorcon, Sanofi Ventures, and T1D Fund.
i2o Therapeutics operates through I2o Therapeutics, Inc.